Jianming Xu
Director of in vivo Pharmacology GemPharmatech
Seminars
Wednesday 3rd December 2025
Preclinical Strategies to Evaluate T-Cell Engagers
2:30 pm
- Explore how T-cell engagers (TCEs) differ from conventional monoclonal antibodies, with therapeutic outcomes shaped by molecular design, binding affinity/avidity, and the need for optimized in vitro assays to predict in vivo efficacy
- Present humanized mouse models that incorporate patient-relevant features such as target antigen expression, effector T-cell activity, and graft-versus-host risk to evaluate therapeutic activity in a clinically meaningful context
- Discuss fully immunocompetent, clinically relevant systems for assessing immunogenicity, anti-drug antibody (ADA) formation, and other potential toxicities to support safer and more effective TCE development
